1)Kawamori R, et al:Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 41:35-43, 1998
2)Olefsky JM:Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467-472, 2000
3)Kawamori R, et al:Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus;Postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76:229-235, 2007
4)Tan MH, et al:Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28:544-550, 2005
5)Dormandy JA, et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events);A randomised controlled trial. Lancet 366:1279-1289, 2005